证券代码：688203 证券简称：海正生材 公告编号：2025-51 浙江海正生物材料股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 大股东的基本情况 截至本公告披露日，浙江海正生物材料股份有限公司（以下简称"公 司"或"海正生材"）持股 5%以上股东中国石化集团资本有限公司（以下 简称"中石化资本"）持有公司股份 12,814,894 股，占公司总股本的 6.32%。 上述股份为公司首次公开发行前取得的股份，并已于 2024 年 2 月 19 日起 上市流通。 减持计划的主要内容 因经营发展资金需求，中石化资本计划拟自本公告披露之日起十五个 交易日后的三个月内，通过集中竞价交易方式减持不超过 2,026,700 股，占 公司总股本比例不超过 1%。上述股份减持价格按减持实施时的市场价格确 定。在减持计划实施期间，公司若发生送股、资本公积金转增股本、增发 新股或配股等变动事项，减持股份数量将根据公司届时最新的总股本数量 及减持计划比例进行相应调整。 1 股东名称 中国石化集团 ...

Group 1 - The core point of the article is that China Petroleum Capital plans to reduce its stake in Zhejiang Haizheng Biological Materials Co., Ltd. by selling up to approximately 2.03 million shares, which represents no more than 1% of the company's total share capital [1] - As of the announcement date, China Petroleum Capital holds about 12.81 million shares, accounting for 6.32% of the total share capital of the company [1] - The shares to be sold were acquired before the company's initial public offering and will be tradable starting from February 19, 2024 [1] Group 2 - The announcement comes amid the company's operational funding needs, indicating a strategic move to manage liquidity [1] - The reduction in stake is planned to occur within three months after the announcement, specifically through centralized bidding transactions [1]

人民财讯9月25日电，海正生材(688203)9月25日公告，公司持股6.32%的股东中国石化集团资本有限公 司(简称"中石化资本")因经营发展资金需求，拟通过集中竞价方式减持不超过202.67万股，减持比例不 超过1%。 ...

Core Viewpoint - China Petroleum & Chemical Corporation (Sinopec) plans to reduce its stake in Haizheng Bio-Materials by selling up to 202.67 million shares, representing no more than 1% of the company's total share capital, due to funding needs for business development [1] Group 1 - The share reduction will occur between October 28, 2025, and January 27, 2026 [1] - The selling price will be determined based on market conditions [1]

智通财经APP讯，海正生材(688203.SH)发布公告，因经营发展资金需求，中石化资本计划拟自公告披 露之日起十五个交易日后的三个月内，通过集中竞价交易方式减持不超过202.67万股，占公司总股本比 例不超过1%。 ...

格隆汇9月25日丨海正生材(688203.SH)公布，因经营发展资金需求，中石化资本计划拟自本公告披露之 日起十五个交易日后的三个月内，通过集中竞价交易方式减持不超过202.67万股，占公司总股本比例不 超过1%。上述股份减持价格按减持实施时的市场价格确定。 ...

Core Viewpoint - China Petroleum Capital Holdings Co., Ltd. plans to reduce its stake in Haizheng Biomaterials by selling up to 2.0267 million shares, representing a maximum reduction of 1% of the total shares held [1] Group 1 - The company currently holds 12.8149 million shares, which accounts for 6.32% of the total shares [1] - The planned reduction will take place within three months, starting from October 28, 2025, to January 27, 2026 [1] - The shares to be sold are sourced from those acquired prior to the company's IPO [1]

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biological Materials Co., Ltd. has experienced a significant decline in stock price, with a drop of 5.07% on September 19, bringing the total market value to 2.923 billion yuan and a cumulative decline of 7.72% over three consecutive days [1] - The company specializes in the research, production, and sales of polylactic acid, with its main business revenue composition being 78.55% from pure polylactic acid, 20.50% from modified polylactic acid, and 0.96% from other sources [1] - The stock's trading volume on the reporting day was 56.7391 million yuan, with a turnover rate of 3.08% [1] Group 2 - According to data from the top ten circulating shareholders, GF Fund's Guangfa Technology Innovation Mixed A Fund has entered the top ten shareholders, holding 7.0478 million shares, which accounts for 5.99% of the circulating shares [2] - The fund has incurred a floating loss of approximately 5.4268 million yuan today and a total floating loss of 8.9507 million yuan during the three-day decline [2] - Guangfa Technology Innovation Mixed A Fund has achieved a year-to-date return of 56.06% and a one-year return of 108.31%, ranking 687 out of 8172 and 428 out of 7980 in its category, respectively [2]

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. has seen a stock price increase of 5.72%, reaching 16.83 CNY per share, with a total market capitalization of 3.41 billion CNY [1] - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1] - The trading volume for the stock was 95.70 million CNY, with a turnover rate of 4.82% [1] Group 2 - According to data, GF Fund's Guangfa Technology Innovation Mixed A Fund (008638) has entered the top ten circulating shareholders of Haizheng Biomaterials, holding 7.05 million shares, which is 5.99% of the circulating shares [2] - The fund has achieved a year-to-date return of 51.91%, ranking 749 out of 8246 in its category, and a one-year return of 99.24%, ranking 499 out of 8054 [2] - The fund's total scale is 2.657 billion CNY, and since its inception, it has returned 136.12% [2] Group 3 - The fund manager of Guangfa Technology Innovation Mixed A is Wu Yuanyi, who has been in the position for 4 years and 352 days [3] - Under Wu's management, the fund's total asset scale is 20.478 billion CNY, with the best return during his tenure being 107.14% and the worst being -15.24% [3]

Company Overview - Zhejiang Haizheng Biomaterials Co., Ltd. is located in Taizhou Bay New District, Zhejiang Province, and was established on August 26, 2004. The company went public on August 16, 2022. Its main business involves the research, production, and sales of polylactic acid (PLA) [1] - The revenue composition of the company includes 78.55% from pure polylactic acid, 20.50% from modified polylactic acid, and 0.96% from other sources [1] Stock Performance - On September 8, Haizheng Biomaterials' stock rose by 5.06%, reaching a price of 17.02 yuan per share, with a trading volume of 110 million yuan and a turnover rate of 5.61%. The total market capitalization is 3.45 billion yuan [1] Shareholder Information - According to data, one of the top ten circulating shareholders of Haizheng Biomaterials is the Guangfa Technology Innovation Mixed Fund A (008638), which entered the top ten in the second quarter with 7.05 million shares, accounting for 5.99% of the circulating shares. The estimated floating profit today is approximately 5.78 million yuan [2] - Guangfa Technology Innovation Mixed Fund A was established on December 25, 2019, with a latest scale of 2.657 billion yuan. Year-to-date returns are 42.42%, ranking 1002 out of 8248 in its category; the one-year return is 79.57%, ranking 755 out of 8051; and since inception, the return is 121.36% [2]